|   Size |   Grade | Involved lymph node | PR status | HER-2 status | Ki-67 status |   LVI |   MVD | Loco-regional treatment | Systemic treatment |
---|---|---|---|---|---|---|---|---|---|---|
 | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) | ( P-value) |
Age (≤50/>50 years) | 0.058 | 0.236 | 0.495 | 0.297 | 0.054 | 0.641 | 0.913 | 0.238 | 0.261 | <0.001 |
Size (≤20/21-50/>50 mm) |  | 0.033 | <0.001 | 0.879 | 0.826 | 0.041 | <0.001 | 0.568 | <0.001 | 0.438 |
Grade (I/II/III) | Â | Â | 0.258 | 0.753 | <0.001 | <0.001 | <0.001 | 0.072 | 0.108 | 0.627 |
Involved lymph node (0/1-3/>3) | Â | Â | Â | 0.157 | 0.323 | 0.035 | <0.001 | 0.607 | 0.001 | 0.013 |
Progesterone –receptor status (PR-/PR+) |  |  |  |  | 0.002 | 0.340 | 0.392 | 0.997 | 0.256 | 0.804 |
HER-2 status (HER-2 -/HER-2+) | Â | Â | Â | Â | Â | 0.020 | 0.119 | 0.627 | 0.363 | 0.603 |
Ki-67 proliferative activity (Low Ki-67/High Ki-67) | Â | Â | Â | Â | Â | Â | 0.049 | 0.041 | 0.598 | 0.289 |
LVI (Absent/Present) | Â | Â | Â | Â | Â | Â | Â | 0.215 | 0.031 | 0.255 |
MVD (tertiles 1, 2, 3) | Â | Â | Â | Â | Â | Â | Â | Â | 0.628 | 0.402 |
Loco-regional treatment (Lumpectomy + radiotherapy/mastectomy + radiotherapy) |  |  |  |  |  |  |  |  |  | 0.057 |